The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Vineet Laboratories Ltd

Vineet Laboratories Ltd

BSE 543298 · NSE VINEETLAB · ISIN INE505Y01010 · Group B · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹38.49

-0.67%

BSE close, 28 August 2026

Market cap

₹73.92 cr

1.9 cr shares · Micro cap

Free float

₹64.71 cr

as published

P/E · P/B

45.8× · 2.40×

EPS ₹0.84 · BV ₹16.04

FY25-26 rev / PAT

59.40 / 1.60

₹ cr, as filed

Filings, window

10

4 selected · 40%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹27.98 52-WK HIGH ₹43.56 ₹38.49 67% of range
Against 52-week high-11.6%
Against 52-week low+37.6%
Day change-0.67%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹0.84
Price / earnings45.82×
Price / book2.40×
Book value — derived, price ÷ P/B₹16.04
Return on equity5.21%
Operating margin13.37%
Net margin6.45%

Consistency check

P/B ÷ P/E, which must equal ROE
5.24%
ROE as published
5.21%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Mar-26 · Q 18.89 1.22 0.43 13.37% 6.45%
Dec-25 · Q 15.65 0.85 0.92 16.22% 5.44%
FY25-26 59.40 1.60 1.00 14.45% 2.70%

Quarter on quarter

Revenue, quarter on quarter
+20.7%
Net profit, quarter on quarter
+43.5%
Operating margin, quarter on quarter
-285 bps

Disclosure profile 10 filings in the window

0 median 17.0 p75 · 25 sector max 52 10 16th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Auditor Resignation1
Board Outcome1
Change in Management1
Results1
Selected sub-total4
Procedural
Board Meeting1
Compliance Certificate1
General1
Monitoring Agency1
Other Update1
Trading Window1
Procedural sub-total6
Total10

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

10 filings · 4 selected · busiest 2026-07-21 and 2026-08-25

Filing rhythm · the twelve most recent

2026-07-212026-10-08

SelectedProcedural

Filings

10 in the window · 1 earlier on record

  1. 8 October 2026 ·

    General

    Clarification Regarding Clerical/Typographical Error In The Cash Flow Statement Of The Audited Financial Results For The Quarter And Year Ended March 31, 2026.

    We are hereby clarify that due to clerical oversight, an amount of Rs. 21.29 Lakhs was erroneously reflected under Inc ome taxes paid in the cash flow statement for the year ended 31st march 2026.

    Company Update / General View filing →

  2. 30 September 2026 ·

    Auditor Resignation

    Resignation of Statutory Auditors

    Resignation of Statutory Auditor

    Company Update / Resignation of Statutory Auditors View filing →

  3. 30 September 2026 ·

    Trading Window

    Closure of Trading Window

    The Trading window for dealing in the securities of the Company will remain closed form 01st October, 2026 till 48 hours after the announcement of Standalone Un-audited Financial Results ....

    Insider Trading / SAST / Closure of Trading Window View filing →

  4. 25 August 2026 ·

    Results

    Results-Delay in Financial Results

    The Board of Director of the company in its meeting held on August 25 2026 Approved the Audited Standalone Financial Results for the fourth quarter and the financial year ended on 31st ....

    Result / Financial Results View filing →

  5. 25 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, August 25, 2026 As Required Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

    The Board of Directors of the company in its meeting held today i.e., on August 25, 2026 has: Approved the Audited Standalone Financial Results of the Company for the fourth quarter and ....

    Board Meeting / Outcome of Board Meeting View filing →

  6. 20 August 2026 ·

    Board Meeting

    Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

    Vineet Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/08/2026 ,inter alia, to consider and approve the Audited Standalone ....

    Board Meeting / Board Meeting View filing →

  7. 14 August 2026 ·

    Monitoring Agency

    Monitoring Agency Report

    Please find the attached Monitoring Agency Report issued by CRISIL rating Limited for quarter ended June 30, 2026

    Company Update / Monitoring Agency Report View filing →

  8. 30 July 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    We are hereby submitting the compliance Certificate issued by Venture Capital and Corporate Inveatments Private Limited

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  9. 21 July 2026 ·

    Other Update

    Resignation of Managing Director

    We are hereby informed that Mr. Gaddam Venkata Ramana ( DIN:00031873) has ceased to hold office of Managing Director of Vineet Laboratories with effect form July 21 2026. It further clarified ....

    Company Update / Resignation of Managing Director View filing →

  10. 21 July 2026 ·

    Change in Management

    Change in Management

    Appointment of Rajesh Kumar Kathulla as an Additional Director (Executive Catagory) of the company with effect from 11th day of June, 2026

    Company Update / Change in Management View filing →

RSS feed for Vineet Laboratories Ltd · the 50 most recent filings